MLAB
Mesa Laboratories, Inc.78.63
+0.80+1.03%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
434.22MP/E (TTM)
-Basic EPS (TTM)
-0.31Dividend Yield
0.01%Recent Filings
8-K
CEO transition to Kadia
Mesa Laboratories announced CEO Gary Owens' departure on or about April 13, 2026, with no disagreements cited. Dr. Siddhartha Kadia, ex-CEO of Calibre Scientific with 20+ years in life sciences, steps in as President, CEO, and Board member on the same date. His deal packs $850,000 base, 100% target bonus, and $6M sign-on equity. Smooth transition ahead.
8-K
Q3 revenues up 3.6%
10-Q
Q3 FY2026 results
Mesa Labs posted Q3 FY2026 revenues of $65.1M, up 3.6% y/y, with operating income jumping 38% to $8.0M on steady 64.2% gross margins. Diluted EPS swung to $0.65 from a $0.31 loss, backed by 5,565k shares. All segments grew except Clinical Genomics, down 7.1% on China weakness, yet margins expanded across the board. Cash hit $29.0M, operations generated $28.9M YTD (FCF not disclosed in the 10-Q), while $166.4M debt drew on a $125M revolver ($26.8M available) and term loan maturing 2029 at 6.2%; covenants met. Converted $97.5M notes to revolver in Aug 2025. China demand stays shaky.
10-Q
Q2 FY2026 results
Mesa Labs posted Q2 FY2026 revenue of $60.7M, up 5.0% y/y from $57.8M but down q/q (derived) from Q1's $59.5M, with YTD $120.3M ahead 3.7% y/y. Gross margins held steady at 61.5% despite tariff and FX headwinds, while operating income rose 34.7% y/y to $4.7M on cost controls; diluted EPS of $0.45 trailed prior $0.63 on higher interest but beat q/q (derived). Biopharma and Calibration segments drove growth, offsetting Clinical Genomics' China weakness. Cash fell to $20.4M amid $10.1M OCF and $2.1M capex (FCF $8.0M), with revolver at $106M (7.1% rate) and $69.4M term debt; convertible notes settled. China demand risks persist.
8-K
Q2 revenues up 5%, AOI strong
Mesa Laboratories reported Q2 FY26 revenues of $60.7M, up 5.0% with core organic growth of 3.7%, driven by BPD's 16.4% surge and CS's 10.8% gain despite CG China's 58% plunge. Operating income jumped 34.7% to $4.7M; non-GAAP AOI excluding unusual items rose 6.1% to 25.1% of revenues. Cost cuts delivered $3.2M annualized savings. Sequential Q3 revenue growth expected.
IPO
Website
Employees
Sector
Industry
A
Agilent Technologies, Inc.
139.19-1.41
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
LAB
Standard BioTools Inc.
1.49-0.02
MASS
908 Devices Inc.
5.78-0.13
MKSI
MKS Inc.
156.25-3.06
MTD
Mettler-Toledo International, I
1386.45-26.02
SCND
Scientific Industries, Inc.
0.55+0.01
TECH
Bio-Techne Corp
57.44-1.25
TMO
Thermo Fisher Scientific Inc
570.16-5.75
WAT
Waters Corporation
378.53-6.89